Pre-hospital administration of tirofiban in diabetic patients with ST-elevation myocardial infarction undergoing primary angioplasty: A sub-analysis of the on-time 2 trial

EuroIntervention

Volumn 6, Issue 3, 2010, Pages 336-342

  Timmer, Jorik R ^a   Ten Berg, Jurriën ^b   Heestermans, Antonius A ^a   Dill, Thorsten ^c   Van Werkum, Jochem W ^b   Dambrink, Jan Henk E ^a   Suryapranata, Harry ^a   Ottervanger, Jan Paul ^a   Hamm, Christian ^c   Van 't Hof, Arnoud W J ^a  

^a ISALA HOSPITAL   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c KERCKHOFF HEART CENTER   (Germany)

Author keywords

Diabetes; Glycoprotein IIb IIIa blockers; Myocardial infarction; PCI

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEMOGLOBIN A1C; HEPARIN; PLACEBO; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; TYROSINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART INFARCTION SIZE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; FOLLOW UP; HEART INFARCTION; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RADIOGRAPHY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; DIABETES MELLITUS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EMERGENCY MEDICAL SERVICES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TYROSINE;

EID: 79952800261     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV6I3A56     Document Type: Article

References (28)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20. (Pubitemid 36050955)
2. Zijlstra F, Ernst N, de Boer MJ, Nibbering E, Suryapranata H, Hoorntje JCA, Dambrink JHE, van 't Hof AWJ, Verheugt FW. Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. J Am Coll Cardiol 2002;39:1733-7. (Pubitemid 34595281)
3. De Luca G, Gibson M, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel M, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, van 't Hof AWJ. Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty (EGYPT) cooperation. An individual patients' data meta-analysis. Heart 2008;94:1548-58.
4. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA 2007;298:765-75. (Pubitemid 47263159)
5. Timmer JR, Ottervanger JP, Thomas K, Hoorntje JCA, de Boer MJ, Suryapranata H, Zijlstra F. Long-term, cause-specific mortality after myocardial infarction in diabetes. Eur Heart J 2004;25:926-31. (Pubitemid 38857866)
6. Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. Eur Heart J 2007;28:443-9. (Pubitemid 47343560)
7. Van 't Hof AWJ, ten Berg J, Heestermans T, Dill T, Funck RC, van Werkum W, Dambrink JHE, Suryapranata H, van Houwelingen G, Ottervanger JP, Stella P, Giannitsis E, Hamm C. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet 2008;372:537-46.
8. De Luca G, Maas AC, Suryapranata H, Ottervanger JP, Hoorntje JCA, Gosselink ATM, Dambrink JHE, de Boer MJ, van 't Hof AWJ. Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction. Am Heart J 2005;150:1248-54.
9. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, Collen D, Feit F, Gore JM, Hillis LD, Lambrew CT, . Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann Intern Med 1991;115:256-65.
10. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M, Steg PG, Gowda N, Gore JM. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 2004;164:1457-63.
11. Timmer JR, Ottervanger JP, de Boer MJ, Boersma E, Grines CL, Westerhout CM, Simes RJ, Granger CB, Zijlstra F. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. Arch Intern Med 2007;167:1353-9. (Pubitemid 47052432)
12. Timmer JR, van der Horst I, De Luca G, Ottervanger JP, Hoorntje JCA, de Boer MJ, Suryapranata H, Dambrink JHE, Gosselink ATM, Zijlstra F, van 't Hof AWJ. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 2005;95:1375-7. (Pubitemid 40719874)
13. Marso SP, Miller T, Rutherford BD, Gibbons RJ, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Mehran R, Krucoff MW, Lansky AJ, Stone GW. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). Am J Cardiol 2007;100:206-10. (Pubitemid 47041980)
14. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Killian JM, Pfeifer EA, Jacobsen SJ, Frye RL, Roger VL. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002;40:946-53. (Pubitemid 34994990)
15. Simon DI, Schmaier AH. Sweet and sticky: diabetic platelets, enhanced reactivity, and cardiovascular risk. J Am Coll Cardiol 2007;50:1548-50.
16. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181-8.
17. Petronio AS, Rovai D, Musumeci G, Baglini R, Nardi C, Limbruno U, Palagi C, Volterrani D, Mariani M. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J 2003;24:67-76. (Pubitemid 36109548)
18. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:533-6. (Pubitemid 35246047)
19. Lee CW, Moon DH, Hong MK, Lee JH, Choi SW, Yang HS, Kim JJ, Park SW, Park SJ. Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:1243-6. (Pubitemid 35346884)
20. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-5. (Pubitemid 41134272)
21. Angiolillo DJ, Bernardo E, Ramirez C, Costa MA, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Bass TA, Macaya C, Fernandez-Ortiz A. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006;48:298-304. (Pubitemid 44026661)
22. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
23. Cannon CP. Importance of TIMI 3 flow. Circulation 2001;104:624-6. (Pubitemid 32738512)
24. van 't Hof AWJ, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet 1997;350:615-9.
25. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel- Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-36.
26. Kim KS, Kim SK, Lee YK, Park SW, Cho YW. Diagnostic value of glycated haemoglobin HbA(1c) for the early detection of diabetes in high-risk subjects. Diabet Med 2008;25:997-1000.
27. Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 2007;24:333-43. (Pubitemid 46452406)
28. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-4. (Pubitemid 34694020)